Dyslipidemia in Type 2 Diabetes (0767-034)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

111 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-07-31

Study Completion Date

2003-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MK0767 in Type 2 Diabetes (0767-012)

NCT00543556

Type 2 Diabetes Mellitus

TERMINATED PHASE2

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

NCT00331487

Diabetes Mellitus

COMPLETED PHASE3

Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus

NCT00308373

Diabetes Mellitus, Type 2

COMPLETED NA

Study A - MK0767 Monotherapy Study

NCT00543517

Diabetes Mellitus, Type 2

TERMINATED PHASE3

Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.

NCT00770653

Diabetes Mellitus Dyslipidemias

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type II Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK0767

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and non-pregnant females
* Age greater than or equal to 21 years
* Stop current diabetes therapy (if applicable)
* Stop current statin therapy (if applicable)

Exclusion Criteria

* History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin
* Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks
* Patients requiring treatment with corticosteroids for more than 14 consecutive days
* Patients taking warfarin or warfarin-like anti-coagulants
* Patients undergoing surgery within 30 days of Visit 1
* Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
* Patients with history of pancreatitis or uncontrolled high blood pressure

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No